Clinical article · Specialties, Medicines and results

The incidental pulmonary nodule: applying the Fleischner Society guidance

Written for
Hospital physicians, emergency doctors and residents
Reading time
7 minutes
Published
Updated

Written by the Sana Health team for clinicians. It summarises published guidance, is not a guideline and has not been peer reviewed. Check current local protocols before acting.

Key points

  • The Fleischner Society guidance covers nodules found incidentally on CT in adults aged 35 or over; screening CTs, known cancer and immunosuppression need other pathways.
  • Most incidental nodules are benign, and comparison with earlier imaging is the single most useful step before any follow-up is planned.
  • Management depends on nodule type (solid, part-solid or ground-glass), size measured in a standard way, and the patient's and the nodule's risk features.
  • Solid nodules under 6 mm in low-risk patients need no routine follow-up; larger nodules need CT surveillance at intervals the guidance gives as ranges.
  • Solid nodules of 8 mm or more call for an active plan: early repeat CT, PET-CT or tissue sampling, decided with the respiratory or multidisciplinary team.
  • Where tuberculosis is common, granulomas are frequent and can be PET-avid, so local guidance and history matter as much as the size table.

First, decide which guidance applies

Nodules are found on a large share of chest CT scans, and at least 95% of them are benign, most often granulomas or intrapulmonary lymph nodes [4]. The 2017 Fleischner Society guidance is written for nodules found incidentally on CT in adults aged 35 or over [1]. It does not apply to CT performed for lung cancer screening, to patients with a known cancer that could metastasise to the lung, or to immunocompromised patients, in whom infection is the more pressing concern.

Screening programmes, which reduced lung cancer mortality in the NLST and NELSON trials [9], use their own reporting system. Lung-RADS, updated in 2022, assigns categories and actions to screen-detected nodules, with its size thresholds unchanged in that version [8]. The British Thoracic Society (BTS) guideline [2] and the American College of Chest Physicians guidance [3] cover similar ground for incidental nodules, and a 2016 consensus adapted the latter for practice in Asia, because patient characteristics there alter the evaluation [6].

Characterise the nodule

  1. Find every previous chest or upper abdominal CT and compare. A solid nodule unchanged for 2 years is considered benign; subsolid nodules need a longer period of stability [5].
  2. Classify it as solid, part-solid or pure ground-glass, because management differs by type [5].
  3. Measure it in the standard way: the average of the long and short axes on the same image, rounded to the nearest millimetre, or volume where volumetry software is used.
  4. Look for features that settle the question: benign patterns of calcification, macroscopic fat, or the typical appearance of a perifissural lymph node.
  5. Note the features that raise concern: spiculation, upper-lobe location, emphysema or pulmonary fibrosis, and growth.

Growth is best judged by volume. In the NELSON screening trial, nodule diameter, volume and volume doubling time each predicted the probability of lung cancer within 2 years, and these measures were used to set management thresholds [7].

Estimate the probability of cancer

Management should begin with an estimate of the pre-test probability of cancer from the patient's risk factors and the CT features, weighed against the harms of investigation for a nodule that turns out to be benign [10]. Fleischner groups patients as low or high risk, using smoking history, age, family history, exposure to asbestos or other carcinogens, and the nodule's size, shape and location [1]. For solid nodules of 8 mm or more, the BTS guideline recommends a formal risk model, the Brock model, and then the Herder model once PET-CT is available [2].

Risk models were derived largely in smokers in Europe and North America. They are less certain in never-smokers and in populations with a high prevalence of tuberculosis or fungal infection, and the result should be read with the history rather than in place of it.

Solid nodules: the follow-up intervals

The 2017 revision raised the size below which no routine follow-up is needed and gave intervals as ranges, so that clinicians can fit them to the patient [1]. For a single solid nodule, the guidance runs as follows.

Nodule sizeLow-risk patientHigh-risk patient
Under 6 mmNo routine follow-upOptional CT at 12 months
6 to 8 mmCT at 6 to 12 months, then consider CT at 18 to 24 monthsCT at 6 to 12 months, then CT at 18 to 24 months
Over 8 mmConsider CT at 3 months, PET-CT or tissue samplingConsider CT at 3 months, PET-CT or tissue sampling

A 7 mm solid upper-lobe nodule in a 58-year-old ex-smoker of 30 pack-years is a high-risk 6 to 8 mm nodule: CT at 6 to 12 months and again at 18 to 24 months, provided the scan was not part of a screening programme and there is no previous imaging showing stability. Multiple nodules are managed by the most suspicious one.

Subsolid nodules

Ground-glass and part-solid nodules are often transient inflammation, so the first step is a repeat CT to confirm that the nodule persists. Persistent subsolid nodules can represent slow-growing adenocarcinoma and need longer surveillance than solid nodules [5]. A new or enlarging solid component within a part-solid nodule is the most worrying change and should prompt referral to the respiratory or thoracic surgical team.

Nodules of 8 mm or more: PET-CT, biopsy or resection

  • PET-CT is most useful when the probability of cancer is low to intermediate; it adds little at very low or high probability or in lesions under about 1 cm [11].
  • Tissue can be obtained by navigational bronchoscopy or CT-guided transthoracic needle biopsy, which have been compared in a randomised trial in peripheral nodules of 10 to 30 mm [12].
  • When the probability of cancer is high and the patient is fit, resection may be both diagnosis and treatment.
  • The choice depends on the nodule's position, the patient's lung function and preferences, and local expertise, and is best made by a multidisciplinary team [3].

In India and other countries where tuberculosis is common, healed granulomas are frequent and active infection can be FDG-avid, which lowers the specificity of PET-CT. Ask about previous tuberculosis and exposure, and follow national and local respiratory guidance where it differs from Fleischner.

Make sure the follow-up happens

Incidental nodules are often found by teams who will not see the patient again. Write the recommended interval and the responsible clinician in the discharge summary or clinic letter, tell the patient why the scan matters, and add the scan to a surveillance list where the hospital keeps one.

How Sana Health helps

Imaging and Report Review takes the CT report, the clinical question and the history, and states first which framework applies: Fleischner for an incidental nodule, Lung-RADS for a screening scan, or neither. It classifies the nodule by type and size, sets out the risk features, gives the follow-up interval or next test with its urgency, and lists every other incidental finding in the report with what to do about each. It suggests questions for the radiologist, such as a comparison with earlier imaging or a volumetric measurement, and ends with verified references.

Questions

Does a 4 mm lung nodule need follow-up?

Under the Fleischner Society 2017 guidance, a solid nodule under 6 mm in a low-risk adult aged 35 or over needs no routine follow-up, and in a high-risk patient a CT at 12 months is optional. This applies only to incidental nodules, not to screening scans or to patients with known cancer or immunosuppression, and local protocols take precedence.

Is a nodule stable for two years always benign?

Two years of stability is the conventional marker that a solid nodule is benign. It does not apply to subsolid nodules, which can be slow-growing adenocarcinomas and need longer surveillance. Stability should be judged on comparable scans, ideally by volume.

When should a pulmonary nodule be referred to the respiratory team?

Referral is appropriate for a solid nodule of 8 mm or more, a part-solid nodule with a solid component, growth on follow-up, or a nodule in a patient with symptoms or other findings suggesting cancer, and earlier where local pathways direct it.

References